Opening of the new manufacturing facility

Has to be any day now…...

At full capacity we estimate that the new manufacturing site will produce over 100,000 units per year within five years,” says Dr Chick. “In Europe alone, there are approximately 100,000 cardiovascular surgical procedures in adults and children, in which our tissue patch could be successfully applied.”

http://f7c7d424d952e13b4dbb-e9c4b54...dical-devices-gaining-a-global-edge-1-1-1.pdf

If Dr Chick is correct within 5 years AHZ will be generating over $150 000 000 from this facility alone (this is assuming the price of the patch remains at $1500.)

If the price of CardioCel rises to $3300 (which would place it at around the middle of patch pricing) then this facility will generate over $330 000 000.

If the price of the patch is at the very top of patch pricing it will generate over $550 000 000.

Whether or not any of these scenarios plays out is yet to be seen although I like their chances (as they have the best product on the market which has been very quickly taken up by surgeons in Australia and around the world and a very proactive management team who get things done.)

There has been some discussion on this recently although as it's opening has to be due very soon I thought it worth revisiting.